Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

Peihua Lu, Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Meiwei Gong, Hui Wang, Jiaqi Chen, Hongxing Liu, Min Xiong, Ying Liu, Lin Wang

Blood blood.2024024861.

https://doi.org/10.1182/blood.2024024861

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Impact of Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)

Blood (2023) 142 (Supplement 1): 6088.

https://doi.org/10.1182/blood-2023-188415

Published: 2023

Journal Articles

Low Erythropoietin to Albumin Ratio in the Serum Predicts Less Reversibility of Renal Impairment with Poorer Prognosis in Multiple Myeloma

Kai Sun, Ying Liu, Yanliang Bai, Haoyan Wang, Mengzhen Wang, Yuan Chen, Li Bao

Blood (2023) 142 (Supplement 1): 6681.

https://doi.org/10.1182/blood-2023-182670

Published: 2023

Journal Articles

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

Xian Zhang, Qinglong Wang, Ying Liu, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 6883.

https://doi.org/10.1182/blood-2023-185361

Published: 2023

Journal Articles

Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL)

Blood (2023) 142 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2023-188761

Published: 2023

Journal Articles

Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1709.

https://doi.org/10.1182/blood-2023-188173

Published: 2023

Journal Articles

Erythroid and Megakaryocytic Differentiation Program in JAK2 -Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm

Blood (2022) 140 (Supplement 1): 9160–9162.

https://doi.org/10.1182/blood-2022-169215

Published: 2022

Journal Articles

Novel Sheep Model of Sickle Cell Disease Reproduces Human Clinical and Laboratory Parameters

Caroline E. Kuczynski, Iuri V. Perisse, Misha Regouski, Elmira Alipour, Cecily LaPradd, Ying Liu, Michael W. Beaty, Daniel B. Kim-Shapiro, Anthony Atala, Irina Polejaeva, Christopher D. Porada, M. Graca Almeida-Porada

Blood (2022) 140 (Supplement 1): 8220.

https://doi.org/10.1182/blood-2022-168050

Published: 2022

Journal Articles

Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

Troy Robinson, Robert L. Bowman, Sonali Persaud, Ying Liu, Qi Gao, Jing-Ping Zhang, Xiaotian Sun, Adam Sciambi, Aaron Llanso, Christopher Famulare, Aaron D Goldberg, Ahmet Dogan, Mikhail Roshal, Ross L. Levine, Wenbin Xiao

Blood (2022) 140 (Supplement 1): 2275–2277.

https://doi.org/10.1182/blood-2022-166501

Published: 2022

Journal Articles

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

Peihua Lu, Ying Liu, Junfang Yang, Xian Zhang, Xiao Yang, Hui Wang, Lin Wang, Qinglong Wang, David Jin, Jianqiang Li, Xiaojun Huang

Blood (2022) 140 (4): 321–334.

https://doi.org/10.1182/blood.2021014498

Published: 2022

Includes: Supplemental data

Journal Articles

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation

Bing Li, Wenbin An, Hua Wang, Timour Baslan, Shoron Mowla, Aishwarya Krishnan, Wenbin Xiao, Richard P. Koche, Ying Liu, Sheng F. Cai, Zhijian Xiao, Andriy Derkach, Ilaria Iacobucci, Charles G. Mullighan, Kristian Helin, Scott W. Lowe, Ross L. Levine, Raajit K. Rampal

Blood (2022) 139 (25): 3630–3646.

https://doi.org/10.1182/blood.2021014465

Published: 2022

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement

Ying Liu, Biping Deng, Bo Hu, Wenqun Zhang, Qing Zhu, Yang Liu, Shan Wang, Pei Zhang, Junhan Yang, Qinlong Zheng, Xinjian Yu, Zifen Gao, Chunju Zhou, Wei Han, Alex Hong Chang, Yonghong Zhang

Blood (2021) 138 (Supplement 1): 257.

https://doi.org/10.1182/blood-2021-146302

Published: 2021

Journal Articles

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Junfang Yang, Xian Zhang, Ying Liu, Xiao Yang, Hui Wang, Lin Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 473.

https://doi.org/10.1182/blood-2021-147667

Published: 2021

Journal Articles

Clinical and Genomic Characterization of Secondary Acute Myeloid Leukemia with Mixed Phenotype

Pallavi Galera, Alexander Chan, Andriy Derkach, Ying Liu, Jeeyeon Baik, Christopher Famulare, Allison Sigler, Maria E. Arcila, Douglas A Mata, Ahmet Dogan, Martin S. Tallman, Ross L. Levine, Yanming Zhang, Mikhail Roshal, Jacob L Glass, Wenbin Xiao

Blood (2021) 138 (Supplement 1): 687.

https://doi.org/10.1182/blood-2021-151263

Published: 2021

Journal Articles

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

Xian Zhang, Junfang Yang, Jingjing Li, Yanze Shi, Yunchao Su, Ying Liu, Min Ba, Yan Wu, Wenqian Li, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2021-146425

Published: 2021

Journal Articles

Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies

Ying Liu, Weijing Li, Lin Wang, Min Ba, Qinglong Wang, Peihua Lu, Lihong Liu, Jianqiang Li

Blood (2021) 138 (Supplement 1): 1696.

https://doi.org/10.1182/blood-2021-149384

Published: 2021

Journal Articles

The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes

Eugene Brailovski, Qing Li, Ning Liu, Brian Leber, Dina Khalaf, Mitchell Sabloff, Grace Christou, Karen Yee, Lisa Chodirker, Anne Parmentier, Mohammed Siddiqui, Alexandre Mamedov, Liying Zhang, Ying Liu, Craig C. Earle, Matthew Cheung, Nicole Mittman, Rena J. Buckstein, Lee Mozessohn

Blood (2021) 138 (Supplement 1): 3064.

https://doi.org/10.1182/blood-2021-149855

Published: 2021

Journal Articles

ALK Inhibitor Plus Vinblasitine for Refractory/Relapsed Pediatric ALK+ Anaplastic Large Cell Lymphoma: A Prospective, One-Arm, Open-Label Real-World Study

Wenqun Zhang, Shan Wang, Jing Yang, Bo Hu, Ying Liu, Ling Jing, Qing Zhu, Yang Liu, Qinlong Zheng, Chunju Zhou, Zifen Gao, Yonghong Zhang

Blood (2021) 138 (Supplement 1): 1406.

https://doi.org/10.1182/blood-2021-149402

Published: 2021

Journal Articles

A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)

Junfang Yang, Xiao Yang, Ying Liu, Qinglong Wang, Hui Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 652.

https://doi.org/10.1182/blood-2021-147754

Published: 2021

Journal Articles

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Blood (2021) 137 (10): 1377–1391.

https://doi.org/10.1182/blood.2020007897

Published: 2021

Includes: Supplemental data

NARROW

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

Prognostic Impact of Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)

Low Erythropoietin to Albumin Ratio in the Serum Predicts Less Reversibility of Renal Impairment with Poorer Prognosis in Multiple Myeloma

Comparative Analysis of Immune Effector Cell-Associated Hematotoxicity (ICAHT) and Infection Incidence Following CD19-Targeted CAR-T Therapy Versus CD7-Targeted CAR-T Therapy

Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL)

Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma

Erythroid and Megakaryocytic Differentiation Program in JAK2 -Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm

Novel Sheep Model of Sickle Cell Disease Reproduces Human Clinical and Laboratory Parameters

Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation

Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Clinical and Genomic Characterization of Secondary Acute Myeloid Leukemia with Mixed Phenotype

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies

The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes

ALK Inhibitor Plus Vinblasitine for Refractory/Relapsed Pediatric ALK+ Anaplastic Large Cell Lymphoma: A Prospective, One-Arm, Open-Label Real-World Study

A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only